SCHEMBL4570714

SCHEMBL4570714

CNC(=O)N1CC(CO)c2cc(C(N)(C(=O)O)S(=O)(=O)c3cc(Cl)cc(Cl)c3)ccc21

nearest known ligand 0.32

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
HTR6 P50406 3/20 0.32
RORC P51449 2/20 0.31
CREBBP Q92793 1/20 0.31
ITGB1 P05556 1/20 0.31
ITGA4 P13612 1/20 0.31
ELOVL6 Q9H5J4 1/20 0.30
ACLY P53396 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4570713 0.77 ADRB2 (0.34) ADRB2ADRB1ADRB3CREBBPITGB1
SCHEMBL2845772 0.75 KEAP1 (0.36)
SCHEMBL11948489 0.71 STS (0.35) RORCITGB1ITGA4
SCHEMBL11956993 0.69 CREBBP (0.31) CREBBP
SCHEMBL2851271 0.64 HTR6 (0.44) ADRB2ADRB1ADRB3HTR6
SCHEMBL2967390 0.61 CYP3A4 (0.37) ACLY
SCHEMBL2925027 0.60 PSEN1 (0.30)
SCHEMBL2844660 0.58 ADRB2 (0.66) ADRB2ADRB1ADRB3HTR6
SCHEMBL11956990 0.57 CREBBP (0.33) CREBBP
SCHEMBL2846832 0.57 ADRB2 (0.48) ADRB2ADRB1ADRB3ACLY

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125718-A2 NEW SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS Boehringer Ingelheim International GmbH (DE) 2009-12-02 EP disclosed
WO-2008113760-A2 ARYLSULPHONYGLYCINE DERIVATIVES AS SUPPRESSORS OF THE INTERACTION OF GLYCOGEN PHOSPHORYLASE A WITH THE GL SUBUNIT OF GLYCOGEN-ASSOCIATED PROTEIN PHOSPHATASE 1 (PPL) FOR THE TREATMENT OF METABOLIC DISORDERS, PARTICULARY DIABETES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-25 WO disclosed